Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $8.50 Average Target Price from Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.50.

Several equities research analysts recently commented on RANI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Rani Therapeutics in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Rani Therapeutics in a report on Friday, January 9th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp acquired a new stake in Rani Therapeutics in the fourth quarter worth $93,000. Farallon Capital Management LLC bought a new position in shares of Rani Therapeutics during the 4th quarter worth about $105,000. Bridgeway Capital Management LLC bought a new position in shares of Rani Therapeutics during the 4th quarter worth about $155,000. Millennium Management LLC acquired a new stake in shares of Rani Therapeutics in the 4th quarter valued at about $220,000. Finally, Citadel Advisors LLC increased its position in Rani Therapeutics by 199.0% in the 3rd quarter. Citadel Advisors LLC now owns 452,542 shares of the company’s stock valued at $226,000 after buying an additional 301,193 shares in the last quarter. 30.19% of the stock is owned by institutional investors.

Rani Therapeutics Stock Up 2.3%

RANI stock opened at $1.31 on Friday. The firm has a market cap of $159.18 million, a price-to-earnings ratio of -1.66 and a beta of 0.41. The company’s fifty day simple moving average is $1.35 and its 200 day simple moving average is $1.20. Rani Therapeutics has a 12-month low of $0.39 and a 12-month high of $3.87.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.